SparingVision to Present at Upcoming Investor Conferences
Paris, December 3, 2021 – SparingVision (or the “Company”), a genomic medicine company developing vision saving treatments for ocular diseases, today announced the upcoming investor conferences that its management team will be participating in:
- UBS Virtual Ophthalmology Day, 6-7 December 2021
- Fireside chat, Stéphane Boissel, President & CEO, December 7th at 9 am ET / 3pm CET
- Kempen Life Sciences Crossover Conference, 6 January 2022
- 40th Annual J.P. Morgan Healthcare Conference, 10-13 January 2022
- Company presentation, Stéphane Boissel, President & CEO
SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments.
Leveraging its unparalleled understanding of retinal diseases, SparingVision has built the world’s most compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for inherited retinal diseases (IRDs). Both of its most advanced products, SPVN06 and SPVN20 look to go beyond single gene correction therapies to deliver new mutation agnostic treatments for Retinitis Pigmentosa (RP), a group of IRDs which are the leading cause of blindness globally. The Company also has a strategic collaboration with Intellia Therapeutics (NASDAQ:NTLA) to develop novel genome editing-based treatments for ocular diseases utilizing CRISPR-Cas9 technology.
SparingVision is backed by high-quality international investors including 4BIO Capital, Advent France Biotechnology, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, Intellia Therapeutics, UPMC Enterprises, Jeito Capital, Ysios Capital.